A Missouri judge has approved a $7.25 billion settlement between Bayer and thousands of U.S. cancer patients who allege that Roundup weed killer caused their non-Hodgkin lymphoma. The agreement, spanning up to 21 years, will provide individual payments averaging between $10,000 and $165,000, dependent on factors like age, illness severity, and exposure duration. Judge Timothy Boyer deemed the settlement “fair, reasonable, and adequate,” a milestone for Bayer in mitigating legal risks inherited from its 2018 acquisition of Monsanto. Bayer CEO Bill Anderson stated the approval is a “decisive milestone” in the company’s strategy. While some lawyers representing plaintiffs criticized the payments as too low, the judge rejected their objections, citing the need to provide compensation to seriously ill patients without further delay. The settlement follows a June Supreme Court ruling that limited the ability of cancer patients to sue Bayer for failing to warn of potential cancer risks on Roundup packaging, and a separate Missouri jury ruling in Bayer’s favor in October. Approximately 200 cases remain in federal courts outside the settlement. Bayer has faced around 200,000 claims since acquiring Monsanto, with Roundup, containing glyphosate, introduced in 1974 and widely used in agriculture and home gardening.
We assess that Bayer has successfully navigated a major legal hurdle, but the risk is not entirely extinguished. The most likely outcome is a gradual reduction in legal costs as the 21-year settlement unfolds, though the approximately 200 remaining federal cases represent a continuing, if diminished, threat. A less likely scenario would involve successful appeals against the settlement, potentially reopening the floodgates of litigation; this would depend on the grounds for appeal and the willingness of plaintiffs’ lawyers to pursue them. The scale of the settlement, at $7.25 billion, is significant and suggests Bayer prioritized minimizing long-term legal exposure over aggressively contesting every claim. This is particularly noteworthy given the company’s recent legal victory at the Supreme Court, which limited plaintiffs’ options. The fact that some lawyers criticized the payments as too low, despite the judge’s approval, hints at ongoing dissatisfaction and potential for future legal challenges, even if outside the scope of this settlement. The Missouri vote on abortion and gender-affirming care, while seemingly unrelated, highlights a pattern of legal battles playing out in the state, and a potential willingness of voters to challenge corporate or legislative decisions. This could influence future litigation against Bayer, or other companies, in Missouri.
Read the original coverage
💬 Comments
📜 Comment Policy